<DOC>
	<DOC>NCT01024231</DOC>
	<brief_summary>The purpose of this study is to determine the safety and tolerability of treatment with BMS-936558 (MDX-1106) in combination with Ipilimumab (BMS-734016) when given at the same time or as a sequenced regimen in subjects with unresectable Stage III or Stage IV malignant melanoma (MEL)</brief_summary>
	<brief_title>Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Histologic diagnosis of malignant melanoma (MEL) Measurable unresectable Stage III or IV MEL ECOG performance status score of 0 or 1 Life expectancy ≥4 months For those enrolled in amendment 5 and later, tumor tissue (archival or recent acquisition) must be available For Cohorts 15, subjects may have been treated with up to 3 prior systemic standard treatments for metastatic melanoma not including any postincisional adjuvant therapy. Subjects may be treatment naïve. All metastatic melanoma regardless of primary site of disease will be allowed For Cohorts 67, subjects may have been treated with up to 3 prior systemic standard treatments for metastatic melanoma; this does not include any postincisional adjuvant therapy. Specifically, subjects must have received ≥3 doses of Ipilimumab therapy and the last dose having been administered within 412 weeks of initiation of study treatment History of severe hypersensitivity reactions to other mAbs Prior malignancy active within the previous 2 years except for localized cancers that are considered to have been cured and in the opinion of the investigator present a low risk for recurrence Active autoimmune disease or a history of known or suspected autoimmune disease History of recently active diverticulitis or symptomatic peptic ulcer disease and history of adrenal insufficiency Regular narcotic analgesia Active, untreated central nervous system metastasis For subjects enrolled in Cohorts 15, prior therapy with an antiPD1, antiPDL1, antiPDL2, antiCD137 or antiCTLA4 antibody For subjects enrolled in Cohorts 67, prior therapy with an antiPD1, antiPDL1, antiPDL2, or antiCD137 antibodies Any nononcology vaccine therapy used for prevention of infectious disease Concomitant therapy with any other anticancer therapy, concurrent medical conditions requiring use of immunosuppressive medications or use of other investigational drugs Positive tests for human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS), hepatitis B, hepatitis C Subjects weighing ≥125 kg are excluded from Cohort 5 Subjects in Cohorts 6 and 7 must have received Ipilimumab monotherapy immediately prior to study entry, but must not have received that Ipilimumab as part of a clinical trial Subjects with ocular melanoma are excluded from Cohort 8</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>